Vimarsana
Biggest News Aggregation in the World

Page 33 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

Brokerages Expect BeiGene, Ltd. (NASDAQ:BGNE) Will Post Quarterly Sales of $332.26 Million - Vimarsana News

Brokerages Expect BeiGene, Ltd. (NASDAQ:BGNE) Will Post Quarterly Sales of $332.26 Million

Equities research analysts expect BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) to report sales of $332.26 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for BeiGene’s earnings, with the highest sales estimate coming in at $347.62 million and the lowest estimate coming in at $316.90 million. BeiGene reported […]

BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress - Vimarsana News

BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress

Data from four pivotal trials continue to build evidence base for BRUKINSA (zanubrutinib) in B-cell malignancies Pipeline showing promise with early data for BGB-11417, a BCL-2 inhibitor, as monotherapy

BeiGene (NASDAQ:BGNE) Downgraded by Zacks Investment Research - Vimarsana News

BeiGene (NASDAQ:BGNE) Downgraded by Zacks Investment Research

BeiGene (NASDAQ:BGNE – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is […]

BeiGene, Ltd.: BeiGene Reports First Quarter 2022 Financial Results - Vimarsana News

BeiGene, Ltd.: BeiGene Reports First Quarter 2022 Financial Results

Recorded product revenue of $261.6 million for the first quarter, representing a 146% increase from $106.1 million in the prior year period BRUKINSA product revenue increased 372% globally

BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) - Vimarsana News

BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for